Sharescart Research Club logo

Symbiox Inv.& Tradig Overview

Symbiox Investment & Trading Co Ltd is an Indian public limited company operating in the financial services and investment sector. The company is engaged in investing in shares, securities, and other financial instruments, as well as trading activities to generate returns for its stakeholders. Its core business activities include portfolio management, investment in equities and debt instruments, and providing financial solutions to clients. Symbiox Investment & Trading Co Ltd is a listed company in India and follows regulatory and corporate go...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Symbiox Inv.& Tradig Key Financials

Market Cap ₹5 Cr.

Stock P/E 27.7

P/B 0.2

Current Price ₹1.7

Book Value ₹ 10.2

Face Value 10

52W High ₹3.8

Dividend Yield 0%

52W Low ₹ 1.4

Symbiox Inv.& Tradig Share Price

| |

Volume
Price

Symbiox Inv.& Tradig Quarterly Price

Show Value Show %

Symbiox Inv.& Tradig Peer Comparison

Symbiox Inv.& Tradig Quarterly Results

#(Fig in Cr.) Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Sep 2024 Dec 2024 Mar 2025 Sep 2025 Dec 2025
Net Sales -0 1 1 0 1 1 0 1 0 0
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income -0 1 1 0 1 1 0 1 0 0
Total Expenditure 1 1 1 0 1 0 0 2 0 0
Operating Profit -1 0 0 -0 -0 0 0 -0 0 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -1 0 0 -0 -0 0 0 -0 0 0
Provision for Tax 0 0 0 -0 -0 0 0 -0 0 0
Profit After Tax -1 0 0 -0 -0 0 0 -0 0 0
Adjustments 0 0 0 0 -0 -0 0 0 -0 0
Profit After Adjustments -1 0 0 -0 -0 0 0 -0 0 0
Adjusted Earnings Per Share -0.3 0 0 -0 -0 0.1 0.1 -0.1 0 0

Symbiox Inv.& Tradig Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1 1 2 2 1 1 2 2 4 4 3 1
Other Income 0 1 1 1 1 1 1 0 0 0 0 0
Total Income 1 2 3 3 2 2 3 2 4 4 3 1
Total Expenditure 1 2 3 3 2 2 3 2 4 4 3 2
Operating Profit 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 0 0 0 0 0 0 0
Provision for Tax 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Tax -0 0 0 0 -0 0 0 0 0 0 0 0
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 0 0 0 -0 0 0 0 0 0 0 0
Adjusted Earnings Per Share 0 0 0 0 -0 0 0 0 0.1 0.1 0.1 0

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -25% 14% 25% 12%
Operating Profit CAGR 0% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -48% -24% 16% -24%
ROE Average 1% 1% 0% 0%
ROCE Average 1% 1% 1% 0%

Symbiox Inv.& Tradig Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 31 31 31 31 31 31 31 31 31 32 32
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0 0
Total Current Liabilities 0 0 1 1 3 1 2 1 1 0 0
Total Liabilities 31 31 32 32 34 32 33 32 33 32 32
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0 0 0 0 0 0 0
Total Current Assets 31 31 32 32 34 32 33 32 33 32 32
Total Assets 31 31 32 32 34 32 33 32 33 32 32

Symbiox Inv.& Tradig Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 1 0
Cash Flow from Operating Activities -1 -17 1 0 1 0 1 -0 -4 -3 4
Cash Flow from Investing Activities 1 17 -1 -0 -2 -0 -1 0 5 3 -3
Cash Flow from Financing Activities 0 0 0 0 0 0 0 0 0 0 0
Net Cash Inflow / Outflow 0 -0 0 0 -0 -0 0 0 0 -0 1
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 1 0 1

Symbiox Inv.& Tradig Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0.01 0.04 0.04 -0 0.01 0.02 0.04 0.05 0.07 0.06
CEPS(Rs) -0.03 0.01 0.04 0.04 -0 0.01 0.02 0.04 0.05 0.07 0.06
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 9.78 9.82 9.86 9.87 9.87 9.9 9.96 10.01 10.08 10.14
Core EBITDA Margin(%) 1.68 -218.94 -63.33 -46.27 -90.9 -89.35 -44.02 9.56 5 0.52 9.35
EBIT Margin(%) 1.68 9.12 8.08 9.61 4.1 3.06 4.52 10.25 5.42 6.37 9.4
Pre Tax Margin(%) 1.68 9.12 8.07 9.56 4.09 3.05 4.51 10.25 5.41 6.35 9.38
PAT Margin (%) -5.99 6.43 5.58 7.1 -1 2.29 3.34 7.59 4 5.34 6.94
Cash Profit Margin (%) -5.99 6.67 5.81 7.29 -1 2.29 3.34 7.59 4 5.4 7.05
ROA(%) -0.56 0.13 0.36 0.41 -0.03 0.07 0.21 0.43 0.49 0.64 0.6
ROE(%) -0.57 0.13 0.37 0.43 -0.03 0.08 0.22 0.45 0.51 0.66 0.61
ROCE(%) 0.16 0.19 0.53 0.57 0.12 0.1 0.3 0.6 0.69 0.79 0.82
Receivable days 0 0 59.13 189.81 582.46 0 0.05 86.54 76.3 38.05 11.33
Inventory Days 3.03 5.68 1.77 1.93 0 0 0 0 19.07 13.94 91.53
Payable days 0 0 43.86 143.4 467.63 386.01 208.67 466.05 108.94 80.46 30.52
PER(x) 0 2015.38 323.06 22.8 0 26.32 40.99 110.36 67.98 40.99 52.04
Price/Book(x) 0 2.68 1.18 0.1 0.06 0.02 0.09 0.49 0.35 0.27 0.31
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 21.18 130.14 18.04 1.63 2.25 0.85 1.3 8.27 2.58 2.11 3.23
EV/Core EBITDA(x) 1262.73 1390.54 217.2 16.61 54.77 27.66 28.73 80.67 47.68 32.88 33.97
Net Sales Growth(%) 0 -56.64 220.18 -8.22 -51.63 15.68 100.26 -11.96 117.6 -2.12 -29.1
EBIT Growth(%) 976.55 135.88 183.49 9.13 -79.34 -13.62 195.44 99.73 14.92 15.1 4.64
PAT Growth(%) -6288.4 146.58 177.7 16.77 -106.81 364.79 192.12 100.12 14.57 30.88 -7.86
EPS Growth(%) 0 0 176.92 16.94 -106.89 362.07 192.11 100 14.64 30.84 -7.96
Debt/Equity(x) 0 0.01 0.01 0.01 0.01 0.01 0 0 0 0 0
Current Ratio(x) 71.75 165.31 33.92 24.05 12.24 37.64 14.37 43.27 22.06 88.32 113.72
Quick Ratio(x) 71.72 165.25 33.91 24.05 12.24 37.64 14.37 43.27 21.92 88.07 109.11
Interest Cover(x) 0 1257.69 1183.29 198.6 274.78 273.46 508.72 0 1215.76 340.06 564.45
Total Debt/Mcap(x) 0 0 0.01 0.09 0.14 0.42 0 0 0 0 0

Symbiox Inv.& Tradig Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33 3.33
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 96.67 96.67 96.67 96.67 96.67 96.67 96.67 96.67 96.67 96.67
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Symbiox Inv.& Tradig News

Symbiox Inv.& Tradig Pros & Cons

Pros

  • Stock is trading at 0.2 times its book value
  • Debtor days have improved from 80.46 to 30.52days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 3.33%.
  • Company has a low return on equity of 1% over the last 3 years.
whatsapp